Axogen VP sells 3,878 shares in open market

Axogen, Inc. Sales VP Doris Quackenbush reported an open‑market sale of 3,878 shares of common stock on May 7, 2026.

Rhea-AI Filing Summary

Axogen, Inc. Sales VP Doris Quackenbush reported an open‑market sale of 3,878 shares of common stock on May 7, 2026. The shares were sold at a weighted average price of $43.507 per share in multiple trades between $43.50 and $44.00. After this transaction, Quackenbush directly holds 92,416 shares of Axogen common stock, as reported in the filing.

Insider Trade Summary

Net Seller: 3,878 shares

Net Sell 1 txn

Insider Quackenbush Doris

Role Sales VP

Sold 3,878 shs ($169K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,878	$43.507	$169K

Holdings After Transaction: Common Stock — 92,416 shares (Direct)

Footnotes (1)

1. F1. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.50 to $44.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 3,878 shares Weighted average sale price: $43.507 per share Price range of sales: $43.50–$44.00 per share +1 more

4 metrics

Shares sold 3,878 shares Open-market sale on May 7, 2026

Weighted average sale price $43.507 per share Common stock sale on May 7, 2026

Price range of sales $43.50–$44.00 per share Multiple transactions comprising the reported sale

Shares owned after transaction 92,416 shares Direct Axogen common stock holdings post-sale

Key Terms

open-market sale, weighted average sale price, Form 4, beneficial ownership

4 terms

open-market sale financial

"The Reporting Person engaged in an open-market sale of common stock."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"The reported price in Column 4 is a weighted average sale price."

Form 4 regulatory

"Details of the transaction are disclosed in a Form 4 insider report."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

beneficial ownership financial

"The reporting shows beneficial ownership of 92,416 shares after the sale."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Axogen (AXGN) report for Doris Quackenbush?

Doris Quackenbush reported selling 3,878 Axogen shares. The Sales VP executed an open‑market sale of common stock at a weighted average price of $43.507 per share on May 7, 2026, as disclosed in a Form 4 insider trading report.

At what price did the Axogen (AXGN) Sales VP sell her shares?

The reported weighted average sale price was $43.507 per share. According to the filing footnote, individual trades occurred in a price range from $43.50 to $44.00 per share, with full pricing detail available upon request from the issuer or regulators.

How many Axogen (AXGN) shares does Doris Quackenbush hold after the sale?

She directly holds 92,416 Axogen common shares after the sale. The Form 4 states that following the 3,878‑share open‑market disposition on May 7, 2026, her remaining direct ownership position is 92,416 shares of the company’s common stock.

What type of insider transaction was reported for Axogen (AXGN)?

The filing reports an open‑market sale of common stock. The transaction is coded “S” on Form 4, meaning a sale in the open market or private transaction, with 3,878 shares sold at a weighted average price of $43.507 per share.

Did the Axogen (AXGN) Form 4 mention multiple trade prices for the sale?

Yes, the sale was executed across multiple prices. A footnote explains the 3,878 shares were sold in separate transactions at prices ranging from $43.50 to $44.00 per share, with detailed trade breakdowns available upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/08/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quackenbush Doris

(Last) (First) (Middle)

13631 PROGRESS BLVD.,

SUITE 400

(Street)

ALACHUA FLORIDA 32615

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sales VP

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2026	05/07/2026	S		3,878	D	$43.507(1)	92,416	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.50 to $44.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Marc Began, as attorney-in-fact for Doris Quackenbush	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)